Biotest Diagnostics

Biotest is a global healthcare company specializing in hematology, clinical immunology, and intensive care medicine. The company develops, manufactures, and markets biological medicinal products primarily derived from human blood plasma, as well as recombinant proteins and monoclonal antibodies. Its extensive product portfolio includes essential therapies such as immunoglobulins, coagulation factors, and albumin used to treat life-threatening diseases and immune disorders. Following its acquisition by Grifols in 2022, Biotest continues to operate as a key player in the plasma-derived therapies market, leveraging its advanced manufacturing facilities in Dreieich, Germany. The company is particularly recognized for its innovative pipeline, including Trimodulin for severe community-acquired pneumonia and next-generation plasma proteins.